CLL Abbreviations in one post: AE— Adverse... - CLL Support
CLL Abbreviations in one post
You need to be a member of this community to see this post.
Read more about...
- Rituximab
- Cyclophosphamide
- Tyrosine
- Bendamustine
- Fludarabine
- Chlorambucil
- FCR
- Chronic leukaemia
- Zydelig
- Rituxan
- MabThera
8 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
Advances in Targeted Therapy for R/R CLL
(These OncLive presentations are intended for medical...
Optimal Treatment Combinations in the Management of CLL/SLL Jeff Sharman, MD Provided by Clinical Care Options, LLC
Optimal Treatment Combinations in the Management of CLL/SLL Jeff Sharman, MD
An installment...
CLL INFORMATION - A developing reliable and current international list of CLL Information & Resources.
We have opened a thread that provides access to many of the key reliable UK and international...
CLL/SLL Roundtable: Updates on Patient Management (including low dose radiation treatment for early stage SLL)
Joshua Brody, MD, Richard Bakst, MD, and Amir Steinberg, MD, of the Icahn School of Medicine at...
CLL Society interview - Dr. Shahzad Mustafa on What it Means to be Immunocompromised for Patients with CLL/SLL January 13, 2023
Dr. Shahzad Mustafa on What it Means to be Immunocompromised for Patients with CLL/SLL January 13,...
Related Posts
- Axi-Cel (anti-CD19 CAR T-cell therapy FMC63-28Z) Induces Durable Remissions in Relapsed CLL, B-Cell Lymphoma
- Treatment-naive or relapsed CLL patients will soon have zanubrutinib/Brukinsa as a treatment option in the EU
- YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
- If you want to learn about CLL text or video
- Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
